Clinical Trial Update: Nattokinase Atherothrombotic Prevention Study [NA]

View source ↗

Summary

Clinical trial on nattokinase for prevention of subclinical atherosclerosis progression and cognitive decline has completed; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cognitive Decline

Drugs mentioned

• Nattokinase (Nattokinase)

Snippet

Sponsor: University of Southern California | Conditions: Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline | NA | Status: COMPLETED | Results posted: 2024-03-19